Please assess the completion status of the following clinical trial:

Trial Title: A Study of Brentuximab Vedotin in Relapsed or Refractory Non-Hodgkin Lymphoma

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically-confirmed NHL (DLBCL only for Parts B and C)~* Relapsed or refractory disease following at least 1 prior systemic therapy~* Measurable disease of at least 1.5 cm as documented by CT~* Eastern Cooperative Oncology Group (ECOG) performance status less than or equal to 2~Exclusion Criteria:~* History of another primary invasive malignancy that has not been in remission for at least 3 years~* Current diagnosis of systemic or cutaneous anaplastic large cell lymphoma or mycosis fungoides~* B cell lymphoma previously treated with only single-agent rituximab (for patients receiving brentuximab vedotin only) or corticosteroids as monotherapy~* Known cerebral/meningeal disease

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Brentuximab vedotin+rituximab (Type: EXPERIMENTAL): None
- Brentuximab vedotin (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).